Table 2.
Immunohistochemical staining characteristics of patients with hepatoid adenocarcinoma in the literature review n (%)
| Number | AFP | Hep Par1 | CEA | CK18 | CK19 | CK20 | CK7 | AE1/AE3 | α1-AT | CD10 | GPC3 | |
| Total | 217 (100) | 177 (91.6) | 24 (38.1) | 37 (78.7) | 22 (100) | 27 (100) | 6 (28.6) | 4 (15.4) | 12 (92.3) | 10 (91) | 5 (62.5) | 10 (100) |
| Stomach | 182 (83.9) | 156 (90.6) | 12 (26.7) | 27 (75.0) | 17 (100) | 16 (100) | 5 (38.5) | 0 (0) | 10 (100) | 7 (87.5) | 0 (0) | 10 (100) |
| Gallbladder | 8 (3.7) | 5 (83.3) | 4 (66.7) | 3 (75) | 1 (100) | 6 (100) | 0 (0) | 2 (33.3) | 1 (100) | 1 (100) | 3 (100) | NA |
| Uterus | 7 (3.2) | 6 (85.7) | NA | 1 (100) | NA | NA | NA | NA | NA | NA | 1 (100) | NA |
| Lung | 5 (2.3) | 4 (100) | 0 (0) | 1 (100) | 1 (100) | 1 (100) | 1 (50) | 2 (0) | NA | NA | 1 (100) | NA |
| Urinary bladder | 4 (1.8) | 4 (100) | 4 (100) | 4 (100) | NA | NA | NA | NA | NA | NA | NA | NA |
| Esophagus | 2 (0.9) | 2 (100) | 1 (50) | NA | NA | NA | NA | NA | NA | 2 (100) | NA | NA |
| Peritoneum | 2 (0.9) | 1 (50) | 1 (100) | NA | 1 (100) | NA | 0 (0) | NA | 1 (50) | NA | NA | NA |
| Retroperitoneum | 1 (< 0.5) | NA | NA | NA | NA | NA | NA | NA | 0 (0) | NA | NA | NA |
| Testis | 1 (< 0.5) | 1 (100) | 0 (0) | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Ovary | 1 (< 0.5) | 1 (100) | NA | 1 (100) | NA | NA | NA | NA | NA | NA | NA | NA |
| Jejunum | 1 (< 0.5) | 1 (100) | 1 (100) | NA | 1 (100) | 1 (100) | 0 (0) | 0 (0) | NA | NA | NA | NA |
| Transverse colon | 1 (< 0.5) | NA | NA | NA | NA | 1 (100) | NA | NA | NA | NA | NA | NA |
| Rectum | 1 (< 0.5) | 1 (100) | 1 (100) | NA | 1 (100) | 1 (100) | 0 (0) | 0 (0) | NA | NA | NA | NA |
| Ureter | 1 (< 0.5) | 1 (100) | NA | NA | NA | 1 (100) | 0 (0) | NA | NA | NA | 0 (0) | NA |
CEA: Carcinoembryonic antigen; CK: Cytokeratin; AE1/AE3: Anti-pancytokeratin AE1/AE3; CD10: Cluster of differentiation 10; α1-AT: α1-Antitrypsin; GPC-3: Glypican 3; AFP: α-fetoprotein; NA: Not available.